164 related articles for article (PubMed ID: 34622951)
21. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
22. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Li Z; Xiao D; Li X; Zhan P; Wang J; Zhang H
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):885-892. PubMed ID: 30807446
[TBL] [Abstract][Full Text] [Related]
23. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents.
Chen S; Yu W; Zhang K; Liu W; Chen Q
Medicine (Baltimore); 2018 May; 97(21):e10832. PubMed ID: 29794774
[TBL] [Abstract][Full Text] [Related]
24. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
25. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
[TBL] [Abstract][Full Text] [Related]
27. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
28. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
30. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.
Eltawil KM; Berry R; Abdolell M; Molinari M
HPB (Oxford); 2012 Mar; 14(3):162-70. PubMed ID: 22321034
[TBL] [Abstract][Full Text] [Related]
31. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients.
Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
BMC Cancer; 2011 May; 11():202. PubMed ID: 21615953
[TBL] [Abstract][Full Text] [Related]
32. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Jung SJ; An S; Woo SM; Kim HB; Koh YH; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2012 Jun; 27(6):1051-6. PubMed ID: 22098152
[TBL] [Abstract][Full Text] [Related]
33. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
34. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
35. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
36. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D
HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
[TBL] [Abstract][Full Text] [Related]
37. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
38. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
Chen K; Zhang H; Zhang LN; Ju SQ; Qi J; Huang DF; Li F; Wei Q; Zhang J
World J Gastroenterol; 2013 May; 19(20):3143-9. PubMed ID: 23716996
[TBL] [Abstract][Full Text] [Related]
39. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.
Eltawil KM; Berry R; Abdolell M; Molinari M
HPB (Oxford); 2012 May; 14(5):341-50. PubMed ID: 22487072
[TBL] [Abstract][Full Text] [Related]
40. Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis.
Mosconi C; Gramenzi A; Biselli M; Cappelli A; Bruno A; De Benedittis C; Cucchetti A; Modestino F; Peta G; Bianchi G; Trevisani F; Golfieri R
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1015-1024. PubMed ID: 32236670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
